fda warning letters glp-1 november 2025 Letter Breakdown: Sterility Failures, Subpotent Drugs, and a Compounding Pharmacy Operating Without Control FDA issues 30 warning letters

There is: No evidence that Epitalon can shrink existing tumors in humans No human clinical trials testing its use in oncology No mechanistic studies confirming how Epitalon affects tumor microenvironments or immune evasion in vivo What we do have is a compelling preventive profile in animal models, especially where aging and genetic susceptibility intersect

Who Should Exercise Additional Caution

Research on tendon and soft-tissue healing gives us models for how BPC-157 may help repair reproductive tissue

125 The expression and activity of the SOP enzymes appear to be strongly related to the H 2 S levels to which the corresponding cells or tissues are exposed